Bios Life Clinical Studies
It's not uncommon to see
a company that manufactures a natural supplement which
they claim helps lower your blood sugar, to cite a clinical study when
referencing their product. However, what most of these companies fail to tell you
is that the study they cited wasn't conducted specifically on their
product.
Rather, the study
they reference was conducted on an ingredient that they're simply using in their product...
An ingredient, in fact, that is available to any nutritional supplement manufacturer.
This is of little value to
a Type 2 Diabetic or Pre-diabetic in knowing whether or not this
supplement will
actually help to lower blood sugar, and more importantly, lower it safely,
consistently, and long term.
One of the primary reasons
why hundreds of medical and health care professionals recommend Bios
Life Slim, and use it in their practice for their Diabetic patients,
their patients wanting to lose weight, and their patients at a high risk
for heart disease, is because of the multiple clinical studies conducted
specifically on Bios Life, and
the impressive results.
Doctors are taught in
medical school to always follow the science when evaluating
any product they recommend for a patient. That's certainly what they did
when investigating Bios Life Slim.
We invite you to review some of these studies
below.
Clinical Study Conducted on the Effects of Bios Life on Type
2 Diabetes
In 2008, Dr.
Peter Verdegem, Unicity Chief Science Officer, Dr. Isabel Martinez, MD,
and Bobbi Horne, both from Blue Mesa Medical Associates in Katy, TX,
presented the results from a clinical study conducted to study the
effect of Biosphere Fiber on Type 2 Diabetes.
Biosphere Fiber,
a component of Bios Life Slim, is comprised of a
proprietary blend of Guar Gum, Gum Arabic, Locust Bean Gum, Citrus
Pectin, Oat Fiber, Maltodextrin, and Beta Glucan.
The study
was conducted on 34 patients who were diagnosed with Type 2 Diabetes and
hypercholesterolemia. The study participants took
Biosphere Fiber twice daily 15 to 20 minutes before meals. The
study measured lipid and glucose levels at the start of the study, and
then after 4 weeks, and again after 8 weeks.
The study concluded that after taking Biosphere
Fiber for 8 weeks:
Results of Bios Life Clinical Study 2008
The study entitled, "Lipid and Glucose
Optimization Using Phytonutrient Combination Therapy in Diabetics,"
was presented at the American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference
held last year in Chicago.
Lipid and glucose
optimization using phytonutrient combination therapy in Diabetes
Isabel
Martinez, MD.1, Bobbi Horne1, Peter J.E. Verdegem, Ph.D., MBA 21 Blue
Mesa Medical Associates, Katy, TX, 2Unicity International, Orem, UT.
Introduction: Dietary approaches to management of lipid and glucose
parameters in diabetes is gaining popularity among patients. Monotherapy
with dietary ingredients has shown positive effects, but with limited
clinical relevance.
Our research
focuses on using a phytonutrient combination in optimizing lipid and
glucose parameters. All four ingredients have individual data supporting
their use for optimizing lipoprotein fractions in hypercholesterolemia.
This pilot study evaluates their combined efficacy in Type-II Diabetes.
Methods:
A group of 34 subjects with established Type-II Diabetes and
hypercholesterolemia added the product to their diet. The drink was
taken thrice daily 15-20 minutes before meals. The fiber drink consists
of viscous soluble fiber, minerals, vitamins, policosanol, phytosterols,
and an aqueous Chrysanthemum Morifolium extract. Lipid and glucose
parameters were measured at baseline, 4 and 8 weeks.
Conclusion:
Bios Life Slim, a phytonutrient combination drink, shows potential in
optimizing parameters associated with cardio vascular disease risk in
Type-II Diabetes. These findings are well in line with previously
reported clinical results. The fiber component has reduced the
post-prandial glucose levels and the resulting lower HbA1c levels
indicate that Bios Life Slim provides a natural option to improve Diabetes
management.
Results from Fiber Supplementation Study
Bios Life Slim is easy to use,
and safe for long-term usage. It's simple to incorporate into a daily
routine, which can lead to higher compliance. Each serving contains a
patented, scientifically-formulated matrix of fibers, vitamins, and
anti-oxidants which the body needs daily.
References:
1. Freed, S. H.; Joffe, D .J. "The Clinical Impact of Fiber
Supplementation for the Reduction of Postprandial Blood Glucose and Risk
Reduction of Complications from Diabetes." Diabetes in Control, Issue 15
(1): 12-18 2000 Aug
2. Bell, D. S. "Importance of postprandial glucose control." South Med
J. 2001 Aug; 94(8):804-9
Bios LifeŽ proved effective in a clinical trial conducted by Independent
Certified Diabetes Educators working with Diabetes in Control.com that
was presented at the 2001 American Association of Certified Diabetes
Educators (AADE) conference.
Summary:
This independent group studied diabetic patients for three months and
gave them Bios LifeŽ twice daily before meals.
Average reduction in postprandial blood glucose of 17.2 percent
Average reduction of fasting blood glucose of 17 percent
Average reduction of total cholesterol of 17 percent
Average reduction of HbA1c of 15.2% in the 1st three months of usage.
(HbA1c is an indicator of average blood sugar levels.)
Average drop in blood pressure of 5 percent
Average drop in body weight of 4 percent (8 pounds)
Average drop in triglycerides of 42 percent
Average increase in HDL cholesterol of 6 percent
When the vascular endpoints are averaged, the study shows an overall
reduction in macro vascular endpoints of 18 percent. And it shows an
overall reduction of micro vascular endpoints of 17 percent.
Additional PDF's on
diabetes research for Bios Life:
*
Bios Life ADA 2005
*
Bios Life Guam ATVB 2005
More Bios Life Clinical Studies...
Cleveland
Clinic Trial by Dr. Dennis Sprecher
Published in Sprecher DL,
Pearce GL (2002) Fiber-multivitamin combination therapy: a beneficial
influence on low density lipoprotein and homocysteine Metabolism 51,
1166-70.
reprint
Diabetes in
Control Study #1 by Steven Freed and David Joffe
Published in Freed S, Joffe D
(2000) The Clinical Impact of Fiber Supplementation for the Reduction of
Postprandial Blood Glucose and Risk Reduction of Complications from
Diabetes, Diabetes in Control 12-8.
abstract
Diabetes in
Control Study #2 by Steven Freed and David Joffe
Published in Freed S, Joffe D
(2004) The Clinical Impact of Fiber Supplementation for the Reduction of
Postprandial Blood Glucose and Risk Reduction of Complications from
Diabetes II Diabetes in Control 212, 17, and Verdegem P, Freed S, Joffe
D (2005) The clinical impact of fiber supplementation for the reduction
of postprandial blood glucose and reduction of complications from Type-2
diabetes Diabetes 54, A425.
abstract
Presented by Verdegem P, Freed
S, Joffe D. The Clinical Impact of Fiber Supplementation on
Cardio-Vascular Risk Parameters in Type-2 Diabetes in 6th
International Conference on Atherosclerosis, Thrombosis and Vascular
Biology. 2005. Washington, DC, USA. The American Heart Association sent
out a press release on the study results.
abstract -
poster -
AHA press release
Presented by Verdegem P, Freed
S, Joffe D. The Clinical Impact of Fiber Supplementation for the
Reduction of Postprandial Blood Glucose and Risk Reduction of
Complications from Type-2 Diabetes. in 65th Scientific Session
American Diabetes Association. 2005. San Diego, CA, USA.
poster
Philippines
Trial by Dr. Yumul
Presented by Balajadia E,
Valerio A, Yumul N. Beneficial effects of Bios Life 2 (Dietary Fiber
Supplement) in patients with dyslipidemia in 34th Annual Convention of
the Philippine College of Physicians. 2004.
reprint
Utah Trial
by Dr. Peter J.E. Verdegem
As published by Verdegem P
(2007) Viscous soluble fiber combined with phytosterols and policosanol
reduces LDL-c and increases HDL-c in hypercholesterolemia Current Topics
in Nutraceutical Research.
reprint
Utah Trial
#2 by Dr. Peter J.E. Verdegem
As presented by Verdegem P,
Duenas V, Duenas J, Burke E. LDL- and HLD-cholesterol optimization using
phytonutrient combination therapy: first line intervention and adjunct
therapy to statins in 1st Asian Preventive Cardiology & Cardiac
Rehabilitation Conference. 2006. Hong Kong.
Presented at the 7th
International Congress on Coronary Artery Disease, 2007, Venice, Italy.
abstract
Pacific Rim
Trial by Dr. Vincent Duenas
Published in Duenas V, Duenas
J, Burke E, Verdegem P (2006) A new fiber drink can serve as an adjunct
therapy to statin medication in mild hypercholesterolemia Arterioscler
Thromb Vasc Biol 26, e53-e107.
abstract
Presented by Duenas V, Duenas
J, Burke E, Verdegem P. A new fiber drink can serve as an adjunct
therapy to statin medication in mild hypercholesterolemia. in 7th Annual
Conference on Arteriosclerosis, Thrombosis and Vascular Biology. 2006.
Denver.
abstract total user group -
poster results total user group -
poster
results statin user group
Texas
Diabetes Trial
by Dr. Isabel Martinez
Presented by Martinez I, Horne
B, Verdegem P. Lipid and glucose optimization using phytonutrient
combination therapy in Diabetes. in 8th Annual Conference on
Arteriosclerosis, Thrombosis and Vascular Biology. 2007. Chicago.
abstract
Keith and Dianne Francis
Irving, Texas
1-888-441-1047 or local 972-869-0502
